Creating new treatments for drug-resistant infections and emerging diseases
Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
This study is working on creating new treatments for infections that don't respond to regular antibiotics, especially for patients dealing with tough bacteria like Acinetobacter and Pseudomonas aeruginosa, so they can have better options for recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Spero Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11177571 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic products to combat drug-resistant infections and emerging infectious diseases. It involves a series of steps including optimizing drug candidates, selecting the best options for further development, and conducting preclinical studies to ensure safety and efficacy. Patients may benefit from innovative treatments that target specific pathogens, particularly those that are resistant to current antibiotics. The research aims to address critical health threats posed by bacteria like Acinetobacter and Pseudomonas aeruginosa.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from infections caused by drug-resistant bacteria or those at risk of emerging infectious diseases.
Not a fit: Patients with infections that are not caused by the targeted drug-resistant bacteria or those who do not have any infectious diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for infections that are currently difficult to manage due to antibiotic resistance.
How similar studies have performed: Other research has shown success in developing new antibiotics and therapies for drug-resistant infections, indicating a promising avenue for this type of research.
Where this research is happening
Cambridge, United States
- Spero Therapeutics, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Kane, Brian — Spero Therapeutics, INC.
- Study coordinator: Kane, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.